在Ad/Pd™ 2026会议上,渤健公司公布了Leqembi®(Lecanemab-Irmb)在美国真实世界长期治疗持久性的研究结果。该数据揭示了该药物在临床实践中的持续应用情况,为阿尔茨海默病治疗领域提供了重要参考。
在Ad/Pd™ 2026会议上,渤健公司公布了Leqembi®(Lecanemab-Irmb)在美国真实世界长期治疗持久性的研究结果。该数据揭示了该药物在临床实践中的持续应用情况,为阿尔茨海默病治疗领域提供了重要参考。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.